{"id":"https://openalex.org/W3097052250","doi":"https://doi.org/10.1182/blood-2020-142423","title":"A Phase I Study of FT819, a First-of-Kind, Off-the-Shelf, iPSC-Derived TCR-Less CD19 CAR T Cell Therapy for the Treatment of Relapsed/Refractory B-Cell Malignancies","display_name":"A Phase I Study of FT819, a First-of-Kind, Off-the-Shelf, iPSC-Derived TCR-Less CD19 CAR T Cell Therapy for the Treatment of Relapsed/Refractory B-Cell Malignancies","publication_year":2020,"publication_date":"2020-11-05","ids":{"openalex":"https://openalex.org/W3097052250","doi":"https://doi.org/10.1182/blood-2020-142423","mag":"3097052250"},"language":"en","primary_location":{"id":"doi:10.1182/blood-2020-142423","doi":"https://doi.org/10.1182/blood-2020-142423","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2020-142423","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5101838284","display_name":"Jae H. Park","orcid":"https://orcid.org/0000-0002-2903-5130","observed_orcids":["https://orcid.org/0000-0002-2903-5130","https://orcid.org/0009-0003-2678-9513"]},"institutions":[{"id":"https://openalex.org/I1334819555","display_name":"Memorial Sloan Kettering Cancer Center","ror":"https://ror.org/02yrq0923","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1334819555"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jae H. Park","raw_affiliation_strings":["Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY","institution_ids":["https://openalex.org/I1334819555"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5021380291","display_name":"Nitin Jain","orcid":"https://orcid.org/0000-0003-0114-8384","observed_orcids":["https://orcid.org/0000-0003-0114-8384"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Nitin Jain","raw_affiliation_strings":["The University of Texas MD Anderson Cancer Center, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The University of Texas MD Anderson Cancer Center, Houston, TX","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101500414","display_name":"Andy Chen","orcid":"https://orcid.org/0000-0001-5204-9445","observed_orcids":["https://orcid.org/0000-0001-5204-9445"]},"institutions":[{"id":"https://openalex.org/I165690674","display_name":"Oregon Health & Science University","ror":"https://ror.org/009avj582","country_code":"US","type":"education","lineage":["https://openalex.org/I165690674"]},{"id":"https://openalex.org/I4210143859","display_name":"Oregon Health and Science University Hospital","ror":"https://ror.org/0488bnd65","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210143859"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Andy Chen","raw_affiliation_strings":["OHSU - Hematologic Malignancies, Portland, OR"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"OHSU - Hematologic Malignancies, Portland, OR","institution_ids":["https://openalex.org/I165690674","https://openalex.org/I4210143859"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5052064208","display_name":"Joseph P. McGuirk","orcid":"https://orcid.org/0000-0002-0539-4796","observed_orcids":["https://orcid.org/0000-0002-0539-4796"]},"institutions":[{"id":"https://openalex.org/I4210128618","display_name":"University of Kansas Medical Center","ror":"https://ror.org/036c9yv20","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210128618"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Joseph P. McGuirk","raw_affiliation_strings":["Department of Blood and Bone Marrow Transplant, The University of Kansas Medical Center, Kansas City, KS"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Blood and Bone Marrow Transplant, The University of Kansas Medical Center, Kansas City, KS","institution_ids":["https://openalex.org/I4210128618"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103967159","display_name":"Monica Diaz","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210155835","display_name":"Fate Therapeutics (United States)","ror":"https://ror.org/04p6jwd33","country_code":"US","type":"company","lineage":["https://openalex.org/I4210155835"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Monica Diaz","raw_affiliation_strings":["Fate Therapeutics Inc., San Diego, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Fate Therapeutics Inc., San Diego, CA","institution_ids":["https://openalex.org/I4210155835"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5070964738","display_name":"Bahram Bob Valamehr","orcid":"https://orcid.org/0000-0002-5917-3585","observed_orcids":["https://orcid.org/0000-0002-5917-3585"]},"institutions":[{"id":"https://openalex.org/I4210155835","display_name":"Fate Therapeutics (United States)","ror":"https://ror.org/04p6jwd33","country_code":"US","type":"company","lineage":["https://openalex.org/I4210155835"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Bahram Valamehr","raw_affiliation_strings":["Fate Therapeutics, Inc., San Diego, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Fate Therapeutics, Inc., San Diego, CA","institution_ids":["https://openalex.org/I4210155835"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5108427126","display_name":"Yu\u2010Waye Chu","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210155835","display_name":"Fate Therapeutics (United States)","ror":"https://ror.org/04p6jwd33","country_code":"US","type":"company","lineage":["https://openalex.org/I4210155835"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Yu-Waye Chu","raw_affiliation_strings":["Fate Therapeutics, Inc., San Diego, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Fate Therapeutics, Inc., San Diego, CA","institution_ids":["https://openalex.org/I4210155835"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5013814515","display_name":"Januario E. Castro","orcid":"https://orcid.org/0000-0003-2785-0892","observed_orcids":["https://orcid.org/0000-0003-2785-0892"]},"institutions":[{"id":"https://openalex.org/I4210127938","display_name":"Mayo Clinic Hospital","ror":"https://ror.org/03660jn93","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1330342723","https://openalex.org/I4210125099","https://openalex.org/I4210127938"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Januario E. Castro","raw_affiliation_strings":["Mayo Clinic, Phoenix, AZ"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Mayo Clinic, Phoenix, AZ","institution_ids":["https://openalex.org/I4210127938"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":7,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":5500,"currency":"USD","value_usd":5500},"apc_paid":null,"fwci":0.6354,"has_fulltext":false,"cited_by_count":16,"citation_normalized_percentile":{"value":0.69314544,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":89,"max":99},"biblio":{"volume":"136","issue":"Supplement 1","first_page":"15","last_page":"16"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11491","display_name":"CAR-T cell therapy research","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11491","display_name":"CAR-T cell therapy research","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10580","display_name":"Immunotherapy and Immune Responses","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10031","display_name":"T-cell and B-cell Immunology","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/off-the-shelf-car-t-cells","display_name":"off-the-shelf CAR T cells","score":0.8669999837875366},{"id":"https://openalex.org/keywords/cd19-car","display_name":"CD19 CAR","score":0.8529999852180481},{"id":"https://openalex.org/keywords/relapsed-refractory-b-cell-malignancies","display_name":"relapsed/refractory B-cell malignancies","score":0.8690000176429749},{"id":"https://openalex.org/keywords/aggressive-b-cell-lymphoma","display_name":"aggressive B-cell lymphoma","score":0.847000002861023},{"id":"https://openalex.org/keywords/pre-b-acute-lymphoblastic-leukemia","display_name":"pre-B acute lymphoblastic leukemia","score":0.9480000138282776},{"id":"https://openalex.org/keywords/graft-versus-host-disease-prophylaxis","display_name":"graft-versus-host disease prophylaxis","score":0.9570000171661377},{"id":"https://openalex.org/keywords/car-t-cell-manufacturing","display_name":"CAR T cell manufacturing","score":0.5830000042915344}],"concepts":[{"id":"https://openalex.org/C3875195","wikidata":"https://www.wikidata.org/wiki/Q5099363","display_name":"Chimeric antigen receptor","level":4,"score":0.7191161513328552},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.540181577205658},{"id":"https://openalex.org/C19317047","wikidata":"https://www.wikidata.org/wiki/Q412037","display_name":"T-cell receptor","level":4,"score":0.4622134566307068},{"id":"https://openalex.org/C2780850621","wikidata":"https://www.wikidata.org/wiki/Q3961647","display_name":"Cytokine release syndrome","level":5,"score":0.45572179555892944},{"id":"https://openalex.org/C2778453870","wikidata":"https://www.wikidata.org/wiki/Q188930","display_name":"B cell","level":3,"score":0.45318669080734253},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.44223445653915405},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.3887039124965668},{"id":"https://openalex.org/C2776090121","wikidata":"https://www.wikidata.org/wiki/Q193529","display_name":"T cell","level":3,"score":0.3434886038303375},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.2393438220024109},{"id":"https://openalex.org/C8891405","wikidata":"https://www.wikidata.org/wiki/Q1059","display_name":"Immune system","level":2,"score":0.1532270312309265}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood-2020-142423","doi":"https://doi.org/10.1182/blood-2020-142423","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2020-142423","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.9922999739646912,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4310106398","https://openalex.org/W3083268149","https://openalex.org/W2988443210","https://openalex.org/W2906950793","https://openalex.org/W3212268081","https://openalex.org/W4411412381","https://openalex.org/W2596980997","https://openalex.org/W3213515770","https://openalex.org/W3095812944","https://openalex.org/W3211360047"],"abstract_inverted_index":{"Background:":[0],"Autologous":[1],"T":[2,50,85,112,150,181,203,218,233,251,259,292],"cells":[3,113,182],"engineered":[4,159,189],"to":[5,92,102,195,216,244,287,325,373,438,457,471,485,493,558,606,613,955,964],"express":[6],"a":[7,107,146,156,171,206,344,434,472,515,523,973],"chimeric":[8],"antigen":[9,16],"receptor":[10,235,261],"(CAR)":[11],"targeting":[12],"the":[13,70,120,137,175,191,197,227,232,265,301,370,375,417,431,440,453,460,559,966],"B-cell":[14,25,331,356],"lineage":[15],"CD19":[17,575],"(CAR19)":[18],"in":[19,36,39,75,88,277,300,304,306,352,467,526,617,909,920,929,962],"patients":[20,76,329,353,476],"with":[21,77,190,330,354,528],"relapsed/refractory":[22],"(r/r)":[23],"aggressive":[24,78],"lymphomas":[26],"(BCL)":[27],"and":[28,61,80,131,139,199,249,254,282,294,296,322,339,364,390,394,410,413,423,447,463,508,531,543,554,577,603,946,968],"pre-B":[29],"acute":[30],"lymphoblastic":[31,312],"leukemia":[32,281,313,362],"(B-ALL)":[33],"have":[34],"resulted":[35],"transformative":[37],"improvements":[38],"clinical":[40,335,348],"outcomes.":[41],"However,":[42],"there":[43],"remain":[44],"significant":[45],"limitations":[46],"concerning":[47],"autologous":[48],"CAR19":[49,84,111,149],"cell":[51,151,163,204,219,234,252,260,284],"manufacturing,":[52],"including":[53,358],"dysfunctional":[54],"starting":[55],"material,":[56],"lack":[57],"of":[58,72,83,110,122,141,178,201,226,258,267,289,311,320,328,350,369,380,387,401,416,430,452,465,474,548,552,562,601,674,693,708,725,740,755,771,783,798,812,830,847,970],"product":[59,152],"consistency":[60],"purity":[62],"following":[63,192],"genetic":[64,414],"engineering,":[65],"manufacturing":[66],"timelines":[67],"that":[68,117,288],"necessitate":[69],"administration":[71,98],"bridging":[73],"therapy":[74,953],"disease,":[79,602],"insufficient":[81],"quantities":[82],"cells,":[86,293],"especially":[87],"severely":[89],"cytopenic":[90],"patients,":[91],"allow":[93],"for":[94,174,183,264,444,505],"more":[95,105],"than":[96,106],"single-dose":[97],"routinely.":[99],"The":[100,318,366,427,449,480,609],"ability":[101,324],"consistently":[103],"administer":[104],"single":[108,516,524],"dose":[109,379,443,488,525,561],"enables":[114],"dosing":[115,499],"schedules":[116],"may":[118],"reduce":[119],"risk":[121],"potentially":[123],"life-threatening":[124],"toxicities":[125],"such":[126,587],"as":[127,170,404,514,522,536,588,951,972],"cytokine":[128],"release":[129],"syndrome":[130],"neurotoxicity,":[132],"while":[133],"maintaining":[134],"or":[135,676,695,710,727,742,757,773,785,800,814,832,849],"improving":[136],"depth":[138],"durability":[140],"anti-tumor":[142,392],"responses.":[143],"FT819":[144,187,271,321,351,388,402,466,487,498,512,520,534,607,956,971],"is":[145,188,343,372,455,611],"first-of-kind,":[147],"off-the-shelf":[148,179],"candidate":[153],"derived":[154],"from":[155,420,491],"clonal":[157],"master":[158],"induced":[160],"pluripotent":[161],"stem":[162],"(iPSC)":[164],"line,":[165],"which":[166,212,240],"can":[167],"be":[168,478,503,949,960],"used":[169,950],"renewable":[172],"source":[173],"mass":[176],"production":[177],"CAR":[180,202,209,228,247,291],"broad":[184],"patient":[185,615],"access.":[186],"features":[193],"designed":[194,456],"improve":[196,326],"safety":[198,389],"efficacy":[200],"therapy:":[205],"novel":[207],"1XX":[208],"signaling":[210],"domain,":[211],"has":[213,241,272],"been":[214,242],"shown":[215,243],"extend":[217],"effector":[220],"function":[221,969],"without":[222],"eliciting":[223],"exhaustion;":[224],"integration":[225],"transgene":[229],"directly":[230],"into":[231],"alpha":[236],"constant":[237],"(TRAC)":[238],"locus,":[239],"promote":[245,965],"uniform":[246],"expression":[248,263],"enhanced":[250],"potency;":[253],"complete":[255],"bi-allelic":[256],"disruption":[257],"(TCR)":[262],"prevention":[266],"graft-versus-host":[268],"disease":[269,569],"(GVHD).":[270],"demonstrated":[273],"antigen-specific":[274],"cytolytic":[275],"activity":[276],"vitro":[278],"against":[279],"CD19-expressing":[280],"lymphoma":[283],"lines":[285],"comparable":[286],"donor-derived":[290],"persists":[295],"maintains":[297],"tumor":[298,418,425],"clearance":[299],"bone":[302],"marrow":[303],"an":[305,671,690,705,722,737,752,768,780,795,809,827,844],"vivo":[307],"disseminated":[308],"xenograft":[309],"model":[310],"(Mandal":[314],"et":[315],"al.":[316],"2020).":[317],"properties":[319],"its":[323],"outcomes":[327],"malignancies":[332],"warrants":[333],"further":[334,458],"investigation.":[336],"Study":[337],"Design":[338],"Methods:":[340],"This":[341],"study":[342],"multicenter,":[345],"Phase":[346,377],"I":[347],"trial":[349,371,432,454,481,610],"r/r":[355,568],"malignancies,":[357],"BCL,":[359,445,506],"chronic":[360],"lymphocytic":[361],"(CLL),":[363],"B-ALL.":[365,448],"primary":[367],"objective":[368],"determine":[374],"recommended":[376],"II":[378],"FT819.":[381,563],"Key":[382,564,581],"secondary":[383],"objectives":[384,398],"include":[385,399,567,584],"evaluation":[386],"tolerability,":[391],"activity,":[393],"pharmacokinetics":[395],"(PK).":[396],"Exploratory":[397],"characterization":[400,415],"pharmacodynamics":[403],"assessed":[405],"by":[406,411],"peripheral":[407],"blood":[408],"biomarkers,":[409],"phenotypic":[412],"microenvironment":[419],"paired":[421],"pre-":[422],"post-treatment":[424],"biopsies.":[426],"dose-escalation":[428,436],"part":[429,451],"utilizes":[433],"3+3":[435],"design":[437],"identify":[439],"maximum":[441,473],"tolerated":[442],"CLL,":[446,507],"dose-expansion":[450],"characterize":[459],"safety,":[461],"efficacy,":[462],"PK":[464],"multiple":[468],"indications.":[469],"Up":[470],"300":[475],"will":[477,482,502,546,948,959],"enrolled.":[479],"test":[483],"up":[484],"four":[486],"levels":[489],"ranging":[490],"30":[492],"900":[494],"million":[495],"cells.":[496],"Three":[497],"regimens":[500],"each":[501],"tested":[504],"B-ALL:":[509],"Regimen":[510,518,532],"A,":[511],"administered":[513,521,535,556,961],"dose;":[517],"A1,":[519],"combination":[527],"interleukin":[529],"(IL)-2;":[530],"B,":[533],"fractionated":[537],"doses":[538],"on":[539,670,689,704,721,736,751,767,779,794,808,826,843],"Days":[540],"1,":[541],"3,":[542],"5.":[544],"Lympho-conditioning":[545],"consist":[547],"three":[549],"consecutive":[550],"days":[551],"fludarabine":[553,947],"cyclophosphamide":[555],"prior":[557,592,954],"first":[560],"inclusion":[565],"criteria":[566,583],"after":[570],"standard":[571],"approved":[572],"therapies,":[573],"documented":[574],"expression,":[576],"adequate":[578],"organ":[579,594],"function.":[580],"exclusion":[582],"ongoing":[585],"immunosuppression":[586],"systemic":[589],"GVHD":[590],"therapy,":[591],"allograft":[593],"transplant,":[595],"active":[596],"central":[597],"nervous":[598],"system":[599],"involvement":[600],"known":[604],"allergy":[605],"components.":[608],"expected":[612],"begin":[614],"recruitment":[616],"2020.":[618],"Disclosures":[619],"Park:":[620],"Novartis:":[621,869],"Consultancy;":[622,643,649,651,657,663],"Fate":[623,819,939],"Therapeutics:":[624,665,683,748,761,820,873,940],"Research":[625,629,632,636,640,646,654,660,666,680,684,699,713,716,730,745,762,788,803,817,821,835,838,852,856,860,863,867,870,876,882,888,894,934,937,941],"Funding;":[626,630,633,637,641,647,655,661,667,681,685,700,714,717,731,746,763,789,804,818,822,836,839,857,861,864,868,871,877,889,935,938],"Amgen:":[627],"Consultancy,":[628,635,639,645,653,659,874,880,892],"Genentech/Roche:":[631],"Kite:":[634],"Incyte:":[638,698],"GSK:":[642],"Autolus:":[644],"Intellia:":[648],"Minverva:":[650],"Takeda:":[652],"AstraZeneca:":[656,805],"Servier:":[658,701],"Allogene:":[662],"Juno":[664,872],"Artiva:":[668],"Membership":[669,688,703,720,735,750,766,778,793,807,825,842],"entity's":[672,691,706,723,738,753,769,781,796,810,828,845],"Board":[673,692,707,724,739,754,770,782,797,811,829,846],"Directors":[675,694,709,726,741,756,772,784,799,813,831,848],"advisory":[677,696,711,728,743,758,774,786,801,815,833,850],"committees.":[678],"Jain:Pfizer:":[679],"ADC":[682],"Janssen:":[686],"Honoraria,":[687,702,719,734,749,765,777,792,806,824,841,875,881,893],"committees;":[697,759,775],"committees,":[712,729,744,787,802,816,834,851],"BMS:":[715],"AbbVie:":[718],"Adaptive":[732],"Biotechnologies:":[733],"TG":[747],"Aprea":[760],"BeiGene:":[764],"Genentech:":[776],"Precision":[790],"Bioscienes:":[791],"Verastem:":[823],"Cellectis:":[837],"Pharmacyclics:":[840,936],"Funding.":[853,895,942],"McGuirk:Bellicum":[854],"Pharmaceutical:":[855],"Gamida":[858],"Cell:":[859],"Astellas:":[862],"Pluristem":[865],"Ltd:":[866],"Kite":[878],"Pharmaceuticals:":[879],"Funding,":[883],"Speakers":[884],"Bureau;":[885],"Fresenius":[886],"Biotech:":[887],"Allo":[890],"Vir:":[891],"Diaz:Fate":[896],"Therapeutics,":[897,902,913],"Inc.:":[898,914],"Current":[899,904,906,915,917,926],"Employment.":[900],"Valamehr:Fate":[901],"Inc:":[903],"Employment,":[905,916],"equity":[907,918,927],"holder":[908,919,928],"publicly-traded":[910,921,930],"company.":[911,931],"Chu:Fate":[912],"company;":[922],"Roche":[923],"Holding":[924],"AG:":[925],"Castro:Kite":[932],"Pharma:":[933],"OffLabel":[943],"Disclosure:":[944],"Cyclophosphamide":[945],"lympho-conditioning":[952],"administration.":[957],"IL-2":[958],"order":[963],"expansion":[967],"T-cell":[974],"product.":[975]},"counts_by_year":[{"year":2026,"cited_by_count":4},{"year":2025,"cited_by_count":4},{"year":2024,"cited_by_count":1},{"year":2023,"cited_by_count":3},{"year":2021,"cited_by_count":4}],"updated_date":"2026-10-08T09:06:37.294493","created_date":"2020-11-09T00:00:00"}